Mechanisms and clinical relevance of bacterial heteroresistance

DI Andersson, H Nicoloff, K Hjort - Nature Reviews Microbiology, 2019 - nature.com
Antibiotic heteroresistance is a phenotype in which a bacterial isolate contains
subpopulations of cells that show a substantial reduction in antibiotic susceptibility …

Building a tuberculosis-free world: The Lancet Commission on tuberculosis

MJA Reid, N Arinaminpathy, A Bloom, BR Bloom… - The Lancet, 2019 - thelancet.com
Executive summary Tuberculosis can be treated, prevented, and cured. Rapid, sustained
declines in tuberculosis deaths in many countries during the past 50 years provide …

[图书][B] WHO consolidated guidelines on tuberculosis. Module 3: diagnosis–rapid diagnostics for tuberculosis detection

World Health Organization - 2024 - books.google.com
The “WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis-Rapid diagnostics
for tuberculosis detection, third edition” is the latest document replacing the one issued in …

Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study

SE Dorman, SG Schumacher, D Alland… - The Lancet infectious …, 2018 - thelancet.com
Summary Background The Xpert MTB/RIF assay is an automated molecular test that has
improved the detection of tuberculosis and rifampicin resistance, but its sensitivity is …

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non …

RL Goodall, SK Meredith, AJ Nunn, A Bayissa… - The Lancet, 2022 - thelancet.com
Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults

JS Zifodya, I Schiller, N Dendukuri… - Cochrane Database …, 2019 - cochranelibrary.com
Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the
newest version, are the only World Health Organization (WHO)‐recommended rapid tests …

Tuberculosis: advances and challenges in development of new diagnostics and biomarkers

G Walzl, R McNerney, N du Plessis, M Bates… - The Lancet Infectious …, 2018 - thelancet.com
Tuberculosis remains the leading cause of death from an infectious disease worldwide.
Early and accurate diagnosis and detection of drug-sensitive and drug-resistant tuberculosis …

Developmental roadmap for antimicrobial susceptibility testing systems

A van Belkum, TT Bachmann, G Lüdke… - Nature Reviews …, 2019 - nature.com
Antimicrobial susceptibility testing (AST) technologies help to accelerate the initiation of
targeted antimicrobial therapy for patients with infections and could potentially extend the …

[HTML][HTML] Emergence of a novel coronavirus causing respiratory illness from Wuhan, China

JW Tang, PA Tambyah, DSC Hui - The Journal of infection, 2020 - ncbi.nlm.nih.gov
In previous reports, workers have characterized the presentation of Middle East Respiratory
Syndrome (MERS) 1 and Severe Acute Respiratory Syndrome (SARS) 2 to aid clinical …

Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance

M Kohli, I Schiller, N Dendukuri… - Cochrane Database …, 2018 - cochranelibrary.com
Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …